摘要
嵌合抗原受体T淋巴细胞（chimeric antigen receptor T lymphocyte，CAR-T）免疫治疗是近年来开始出现的一种新型肿瘤免疫治疗方法，目前已经在白血病、淋巴瘤等晚期癌症患者中应用，并取得一定疗效。神经母细胞瘤是儿童最常见的颅外恶性实体肿瘤之一，有超过一半的患者在确诊时已经发生了转移。目前高危患儿的预后较差，临床需要寻找新的治疗方法。该文总结了CAR-T的基本结构及优化发展，讨论了其在神经母细胞瘤中的治疗原理及风险，并展望了CAR-T在实体肿瘤中的治疗前景。
Chimeric antigen receptor T lymphocyte immunological therapy（CAR-T） is a new oncologic immunotherapy in recent years, which has been widely used in patients with leukemia and lymphoma and achieved a certain effect. Neuroblastoma is one of the most common extracranial solid tumors in children and over 50% of patients have metastatic recurrence when first diagnosed. The prognosis for the high-risk neuroblastoma remains poor at the moment and it＇s time to look for new treatments. In this review, we summarize the basic structure and development of CAR-T, discuss the principles and risks of CAR-T in the treatment of neuroblastoma, and give an outlook to CAR-T in the treatment of solid tumors.
出处
《国际儿科学杂志》
2017年第2期132-134,共3页
International Journal of Pediatrics
